Isomorphic Labs

Isomorphic Labs is a UK-based AI-for-drug-discovery company spun out of Google DeepMind in 2021. It applies AlphaFold-family methods, together with its proprietary IsoDDE drug-design engine, to design small-molecule therapeutics, and as of April 2026 it described itself as gearing up to enter clinical trials.

Snapshot

Funding

Pipeline milestones

Overview

Isomorphic Labs is the AI-for-drug-discovery company spun out of Google DeepMind in 2021, operating as an Alphabet subsidiary and spinoff. It is led by CEO Demis Hassabis, who is also CEO of Google DeepMind, with Max Jaderberg as president, and states its mission as to "solve all disease." Its scientific lineage runs through DeepMind's protein-structure work, which earned Hassabis and John Jumper the 2024 Nobel Prize in Chemistry. (Source: wired.com)

Technology

Isomorphic builds on Google DeepMind's AlphaFold platform, now AlphaFold 3 (2024). AlphaFold 3 is the first version capable of predicting joint protein–small-molecule structures at scale, the directly drug-relevant capability, and commercial use of AlphaFold 3 is routed through Isomorphic Labs.

Its proprietary IsoDDE drug-design engine was announced in early 2026. Isomorphic claims IsoDDE more than doubles AlphaFold 3 accuracy on its target tasks, and the accompanying technical paper claims a more than 2× accuracy improvement over AlphaFold 3. (Source: zenodo.org)

Partnerships

Pipeline

Isomorphic's internal pipeline is focused on oncology and immunology, per Jaderberg at WIRED Health (April 16, 2026). Jaderberg said the engineered molecules target "much lower dose, lower side effects, off-target effects" by leveraging deeper structural understanding. (Source: wired.com)

As of WIRED Health London on April 16, 2026, Jaderberg described the company as "gearing up to go into the clinic." The original target, stated by Hassabis to the Financial Times in 2024, had been to enter the clinic by the end of 2025, a timeline that slipped. (Source: wired.com)

Funding

Isomorphic announced its first external funding round of $600 million in 2024, framed as gearing up for clinical trials. (Source: isomorphiclabs.com) On May 8, 2026, Bloomberg reported the company was in advanced talks to raise more than $2 billion in a round led by Thrive Capital, with Alphabet participating. (Source: bloomberg.com)

Relation to AI policy

Isomorphic is cited as an example of frontier AI being routed into a commercial drug pipeline, relevant to the AI-for-science discourse and to "compressed 21st century" arguments about AI-driven biomedical acceleration; whether its first clinical trials succeed is treated as a data point in those debates.

Isomorphic is also cited as the proximate reason AlphaFold 3 was not released under the same open terms as AlphaFold 2: commercial drug-design value drove Alphabet to gate access, an instance of frontier capability driving toward closure (see AlphaFold (DeepMind) and open-source AI).

As Isomorphic's pipeline advances, biosecurity frameworks (RSP bioweapon-uplift thresholds, BWC discussions) are increasingly tested against an active commercial drug-discovery actor rather than a research artifact alone.

Relationships

• related: Google DeepMind (parent / spinoff origin), Demis Hassabis (CEO), Max Jaderberg (President), John Jumper (AlphaFold co-architect), AlphaFold, IsoDDE.
• deploys-in: Healthcare (drug discovery).
• instance-of: AI for Science.
• related: AI Biosecurity, Compressed 21st Century (Amodei biology vision), Machines of Loving Grace.